Literature DB >> 12067331

Thyroid gland neurofibroma in a NF1 patient.

M Anagnostouli1, G Piperingos, C Yapijakis, P Gourtzelidis, S Balafouta, C Zournas, D Vassilopoulos, D Koutras, C Papageorgiou.   

Abstract

Neurofibromas are a hallmark of neurofibromatosis type 1 (NF1). They are usually benign and rarely present in the thyroid gland region. There is a suspected association between NF1 and intramedullary thyroid carcinoma and there is a well-known association between NF1 and pheochromocytoma. Here, we present a 55-year-old man with typical symptoms of NF1, whose course was complicated by a neurofibroma of the thyroid gland. His clinical spectrum of symptoms included bilateral cataract established before the age of 35 years, quadriparesis and an intrathoracic mass. The patient died because of abdominal carcinomatosis of unknown origin. The rarity of thyroid gland neurofibroma is discussed here, emphasizing the importance of early detection of these and other NF1 complications, also including the risk of malignant transformation with lethal outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12067331     DOI: 10.1034/j.1600-0404.2002.01159.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Thyroid neurofibroma in a female patient with neurofibromatosis type I: report of a case.

Authors:  T Doulias; B Papaziogas; J H Rosser; I Koutelidakis
Journal:  BMJ Case Rep       Date:  2013-06-05

2.  Neurofibroma adjacent to the thyroid gland and a thyroid papillary carcinoma in a patient with neurofibromatosis type 1: report of a case.

Authors:  Yavuz Koksal; Mustafa Sahin; Hande Koksal; Hasan Esen; Metin Sen
Journal:  Surg Today       Date:  2009-09-27       Impact factor: 2.549

Review 3.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.